PortalPublikationenTherapy of clinical stage IIA and IIB seminoma: a systematic...

Therapy of clinical stage IIA and IIB seminoma: a systematic review

Standard

Therapy of clinical stage IIA and IIB seminoma: a systematic review. / Heinzelbecker, Julia; Schmidt, Stefanie; Lackner, Julia; Busch, Jonas; Bokemeyer, Carsten; Classen, Johannes; Dieing, Annette; Hakenberg, Oliver; Krege, Susanne; Papachristofilou, Alexandros; Pfister, David; Ruf, Christian; Schmelz, Hans; Schmidberger, Heinz; Souchon, Rainer; Winter, Christian; Zengerling, Friedemann; Kliesch, Sabine; Albers, Peter; Oing, Christoph.

in: WORLD J UROL, Jahrgang 40, Nr. 12, 12.2022, S. 2829-2841.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Heinzelbecker, J, Schmidt, S, Lackner, J, Busch, J, Bokemeyer, C, Classen, J, Dieing, A, Hakenberg, O, Krege, S, Papachristofilou, A, Pfister, D, Ruf, C, Schmelz, H, Schmidberger, H, Souchon, R, Winter, C, Zengerling, F, Kliesch, S, Albers, P & Oing, C 2022, 'Therapy of clinical stage IIA and IIB seminoma: a systematic review', WORLD J UROL, Jg. 40, Nr. 12, S. 2829-2841. https://doi.org/10.1007/s00345-021-03873-5

APA

Heinzelbecker, J., Schmidt, S., Lackner, J., Busch, J., Bokemeyer, C., Classen, J., Dieing, A., Hakenberg, O., Krege, S., Papachristofilou, A., Pfister, D., Ruf, C., Schmelz, H., Schmidberger, H., Souchon, R., Winter, C., Zengerling, F., Kliesch, S., Albers, P., & Oing, C. (2022). Therapy of clinical stage IIA and IIB seminoma: a systematic review. WORLD J UROL, 40(12), 2829-2841. https://doi.org/10.1007/s00345-021-03873-5

Vancouver

Heinzelbecker J, Schmidt S, Lackner J, Busch J, Bokemeyer C, Classen J et al. Therapy of clinical stage IIA and IIB seminoma: a systematic review. WORLD J UROL. 2022 Dez;40(12):2829-2841. https://doi.org/10.1007/s00345-021-03873-5

Bibtex

@article{266a0ebae85d464797374b8f99b095cb,
title = "Therapy of clinical stage IIA and IIB seminoma: a systematic review",
abstract = "PURPOSE: The optimal treatment for clinical stage (CS) IIA/IIB seminomas is still controversial. We evaluated current treatment options.METHODS: A systematic review was performed. Only randomized clinical trials and comparative studies published from January 2010 until February 2021 were included. Search items included: seminoma, CS IIA, CS IIB and therapy. Outcome parameters were relapse rate (RR), relapse-free (RFS), overall and cancer-specific survival (OS, CSS). Additionally, acute and long-term side effects including secondary malignancies (SMs) were analyzed.RESULTS: Seven comparative studies (one prospective and six retrospective) were identified with a total of 5049 patients (CS IIA: 2840, CS IIB: 2209). The applied treatment modalities were radiotherapy (RT) (n = 3049; CS IIA: 1888, CSIIB: 1006, unknown: 155) and chemotherapy (CT) or no RT (n = 2000; CS IIA: 797, CS IIB: 1074, unknown: 129). In CS IIA, RRs ranged from 0% to 4.8% for RT and 0% for CT. Concerning CS IIB RRs of 9.5%-21.1% for RT and of 0%-14.2% for CT have been reported. 5-year OS ranged from 90 to 100%. Only two studies reported on treatment-related toxicities.CONCLUSIONS: RT and CT are the most commonly applied treatments in CS IIA/B seminoma. In CS IIA seminomas, RRs after RT and CT are similar. However, in CS IIB, CT seems to be more effective. Survival rates of CS IIA/B seminomas are excellent. Consequently, long-term toxicities and SMs are important survivorship issues. Alternative treatment approaches, e.g., retroperitoneal lymph node dissection (RPLND) or dose-reduced sequential CT/RT are currently under prospective investigation.",
author = "Julia Heinzelbecker and Stefanie Schmidt and Julia Lackner and Jonas Busch and Carsten Bokemeyer and Johannes Classen and Annette Dieing and Oliver Hakenberg and Susanne Krege and Alexandros Papachristofilou and David Pfister and Christian Ruf and Hans Schmelz and Heinz Schmidberger and Rainer Souchon and Christian Winter and Friedemann Zengerling and Sabine Kliesch and Peter Albers and Christoph Oing",
note = "{\textcopyright} 2021. The Author(s).",
year = "2022",
month = dec,
doi = "10.1007/s00345-021-03873-5",
language = "English",
volume = "40",
pages = "2829--2841",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "12",

}

RIS

TY - JOUR

T1 - Therapy of clinical stage IIA and IIB seminoma: a systematic review

AU - Heinzelbecker, Julia

AU - Schmidt, Stefanie

AU - Lackner, Julia

AU - Busch, Jonas

AU - Bokemeyer, Carsten

AU - Classen, Johannes

AU - Dieing, Annette

AU - Hakenberg, Oliver

AU - Krege, Susanne

AU - Papachristofilou, Alexandros

AU - Pfister, David

AU - Ruf, Christian

AU - Schmelz, Hans

AU - Schmidberger, Heinz

AU - Souchon, Rainer

AU - Winter, Christian

AU - Zengerling, Friedemann

AU - Kliesch, Sabine

AU - Albers, Peter

AU - Oing, Christoph

N1 - © 2021. The Author(s).

PY - 2022/12

Y1 - 2022/12

N2 - PURPOSE: The optimal treatment for clinical stage (CS) IIA/IIB seminomas is still controversial. We evaluated current treatment options.METHODS: A systematic review was performed. Only randomized clinical trials and comparative studies published from January 2010 until February 2021 were included. Search items included: seminoma, CS IIA, CS IIB and therapy. Outcome parameters were relapse rate (RR), relapse-free (RFS), overall and cancer-specific survival (OS, CSS). Additionally, acute and long-term side effects including secondary malignancies (SMs) were analyzed.RESULTS: Seven comparative studies (one prospective and six retrospective) were identified with a total of 5049 patients (CS IIA: 2840, CS IIB: 2209). The applied treatment modalities were radiotherapy (RT) (n = 3049; CS IIA: 1888, CSIIB: 1006, unknown: 155) and chemotherapy (CT) or no RT (n = 2000; CS IIA: 797, CS IIB: 1074, unknown: 129). In CS IIA, RRs ranged from 0% to 4.8% for RT and 0% for CT. Concerning CS IIB RRs of 9.5%-21.1% for RT and of 0%-14.2% for CT have been reported. 5-year OS ranged from 90 to 100%. Only two studies reported on treatment-related toxicities.CONCLUSIONS: RT and CT are the most commonly applied treatments in CS IIA/B seminoma. In CS IIA seminomas, RRs after RT and CT are similar. However, in CS IIB, CT seems to be more effective. Survival rates of CS IIA/B seminomas are excellent. Consequently, long-term toxicities and SMs are important survivorship issues. Alternative treatment approaches, e.g., retroperitoneal lymph node dissection (RPLND) or dose-reduced sequential CT/RT are currently under prospective investigation.

AB - PURPOSE: The optimal treatment for clinical stage (CS) IIA/IIB seminomas is still controversial. We evaluated current treatment options.METHODS: A systematic review was performed. Only randomized clinical trials and comparative studies published from January 2010 until February 2021 were included. Search items included: seminoma, CS IIA, CS IIB and therapy. Outcome parameters were relapse rate (RR), relapse-free (RFS), overall and cancer-specific survival (OS, CSS). Additionally, acute and long-term side effects including secondary malignancies (SMs) were analyzed.RESULTS: Seven comparative studies (one prospective and six retrospective) were identified with a total of 5049 patients (CS IIA: 2840, CS IIB: 2209). The applied treatment modalities were radiotherapy (RT) (n = 3049; CS IIA: 1888, CSIIB: 1006, unknown: 155) and chemotherapy (CT) or no RT (n = 2000; CS IIA: 797, CS IIB: 1074, unknown: 129). In CS IIA, RRs ranged from 0% to 4.8% for RT and 0% for CT. Concerning CS IIB RRs of 9.5%-21.1% for RT and of 0%-14.2% for CT have been reported. 5-year OS ranged from 90 to 100%. Only two studies reported on treatment-related toxicities.CONCLUSIONS: RT and CT are the most commonly applied treatments in CS IIA/B seminoma. In CS IIA seminomas, RRs after RT and CT are similar. However, in CS IIB, CT seems to be more effective. Survival rates of CS IIA/B seminomas are excellent. Consequently, long-term toxicities and SMs are important survivorship issues. Alternative treatment approaches, e.g., retroperitoneal lymph node dissection (RPLND) or dose-reduced sequential CT/RT are currently under prospective investigation.

U2 - 10.1007/s00345-021-03873-5

DO - 10.1007/s00345-021-03873-5

M3 - SCORING: Review article

C2 - 34779882

VL - 40

SP - 2829

EP - 2841

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 12

ER -